Efficacy of Intermittent Phototherapy versus Continuous Phototherapy for Treatment of Neonatal Hyperbilirubinaemia: A Systematic Review and Meta‐analysis

Abstract

Aims We review the current literatures to determine whether intermittent phototherapy is more effective than continuous phototherapy in treating neonatal hyperbilirubinaemia. Design The systematic review is a systematic review and meta‐analysis. The Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines were used for reporting methods and results of synthesis with meta‐analysis. Synthesis Without Meta‐analysis (SWIM) guidelines were used for reporting methods and results of synthesis without meta‐analysis. Data Source Pubmed, Embase, Cochrane library, China National Knowledge Infrastructure, China Biology Medicine, VIP Database, and Wanfang Database. Review methods PICOS eligibility criteria were used to select original studies published from 1984 through 2019. Data were statistically extracted and evaluated using RevMan 5.3 software. Results A total of 416 records were identified through database searching. Four studies (three randomized studies and one retrospective study) meet the final inclusion criteria. Seven hundred and sixteen neonates were included in the meta‐analysis. There was no difference in the treatment efficacy and total serum bilirubin (TSB), while there was a significant difference in phototherapy duration and side effects after treatment of intermittent phototherapy and continuous phototherapy for neonatal hyperbilirubinaemia. Conclusion Intermittent phototherapy appeared to be as effective as continuous phototherapy for the treatment of neonatal hyperbilirubinaemia and is safer than continuous phototherapy. Healthcare organizations and health workers should choose intermittent phototherapy as the preferred therapy for neonatal hyperbilirubinaemia. Impact Intermittent phototherapy is an effective, feasible, and safer treatment method for the infants with hyperbilirubinaemia in paediatric department. Healthcare organizations and health workers should choose intermittent phototherapy as the preferred therapy for neonatal hyperbilirubinaemia.

Nursing homes during the COVID-19 pandemic: a scoping review of challenges and responses

“…Video calls alongside letters and telephone calls were reported to aid in reducing depression among nursing home residents, and were also associated with positive social interaction, decreased loneliness, and better quality of life [ 74 , 75 ]. Some video-calling modalities posed problems for older users, including auditory interference and a lack of familiarity with the technology [ 76 ], highlighting the need for the development of technology that is specifically tailored to older people. Another technology known as simulated presence therapy, whereby video messages are frequently exchanged between family and the older person, led to the enhanced well-being of residents living with dementia and decreased behavioural and psychological symptoms [ 77 ].…”

Effect of Ursodeoxycholic Acid in Unconjugated Hyperbilirubinemia in the Term Neonates Treated with Phototherapy: A Systematic Review

“…However, a recent systematic review concluded that both intermittent and continuous PT appeared to be equally effective for treating UH. 43 El-Sakka et al 44 reported that although PT effectively decreased UCB levels in breastfed neonates, these neonates demonstrate a slower response to PT than a bottle or mixed-fed neonates. However, the result of the studies with breastfed participants in our research showed a similar reduction of TSB levels as others studies.…”

Impact of Protein Binding Capacity and Daily Dosage of a Drug on Total Serum Bilirubin Levels in Susceptible Infants

“…Despite the fact that metalloporphyrins [ 38 ], Sn-mesoporphyrin [ 11 ], ursodeoxycholic acid [ 39 ], and phenobarbital [ 40 , 41 ] have been proposed as alternative approaches for preventing or treating neonatal hyperbilirubinemia, and melatonin promotes neuroprotective brain-derived neurotrophic factor expression in neonatal hemolytic hyperbilirubinemia [ 42 ], phototherapy is the current model. Phototherapy was first introduced in 1958 for the treatment of neonatal hyperbilirubinemia [ 43 ]. In a hospital setting, the blue part of the spectrum near the wavelength peak of 460 nm, is a safe and effective treatment without major side effects [ 44 , 45 ].…”